Kitazato (368A) · InitiativeAdvanced
Sales of New and Improved Oocyte Retrieval Needles and Catheters
First written in FY2026-H1. 1 of 2 entries say "Advanced", first in FY2026. Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Expanding domestic sales through new products and core high-value-added productsA theme 5 companies write about · 0 as a headwind · 5 as a tailwind
3 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「In Japan, sales amounted to ¥3,660 million, up 4.7% year on year, due to strengthened sales activities, including thorough follow-up with customers, both existing and new, amid stable demand for medical devices.」
The strengthening of domestic sales activities is reported, and domestic sales increased 4.7% year on year. - FY2026-H1First statedAnnual report
「In Japan, sales of new and improved egg retrieval needles and catheters continued to perform well, resulting in sales of ¥1,800 million, up 3.0% year on year.」
Specific product groups supporting domestic sales and their sales results are presented.